ICS2 Antibody

ICAM-2 (CD102) Antibodies

ICAM-2 (Intercellular Adhesion Molecule 2), also known as CD102, is a 55–65 kDa transmembrane glycoprotein critical for leukocyte-endothelial interactions. The CBR-IC2/2 monoclonal antibody (clone CBR-IC2/2) is a well-characterized reagent targeting this protein .

Applications in Research

Clinical Relevance

• Disease Associations: Linked to colon carcinoma in situ and immune dysregulation .

• Therapeutic Potential: Investigated in autoimmune diseases and transplant rejection due to its role in leukocyte trafficking .

Anti-IC2 (DYNC1I2) Antibodies

IC2 is a synonym for DYNC1I2, encoding dynein cytoplasmic 1 intermediate chain 2. These antibodies target a 71.5 kDa cytoplasmic protein involved in dynein-mediated cargo transport .

Research Applications

• Immunofluorescence: Visualizes dynein complexes in cytoskeletal networks.

• Western Blot: Validated in detecting endogenous DYNC1I2 in cell lysates.

• Immunoprecipitation: Isolates dynein intermediates for mechanistic studies .

Comparative Analysis

Immune Complexes (ICs) and Therapeutic Antibodies

• IC Formation: Drug/anti-drug antibody complexes (e.g., in COVID-19 mAbs) can alter pharmacokinetics. Size-defined ICs (dimers to hexamers) are used to study immune responses .

• COVID-19 mAb Resistance: Spike mutations post-mAb treatment (e.g., sotrovimab) correlate with prolonged viral clearance (median 63 days) .

SARS-CoV-2 Antibody Mechanisms

• Broad Neutralization: mAbs like 17T2 show efficacy against Omicron subvariants (BA.1, XBB.1.5) by targeting conserved epitopes outside the RBD .

• Hybrid Immunity: Combined infection/vaccination induces antibodies against both S1 and S2 domains, enhancing ADCC activity .

Key Challenges and Future Directions

• Nomenclature Clarity: "ICS2" is not a standardized term; researchers must differentiate between ICAM-2 and DYNC1I2 targets.

• Therapeutic Optimization: For COVID-19 mAbs, target anti-S IgG levels >5,000 AU achieve >90% ACE2 binding inhibition, reducing breakthrough infections .

• Resistance Monitoring: Viral sequencing is critical post-mAb therapy to detect spike mutations (e.g., E484K, N501Y) .